Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6086
Sealed predictions
- STK36 in dopamine neurons, braak-0.12 (p 0.756) → -0.50 (p 0.173)receipt 6093
Swarm cases
receipt 6093: STK36 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.214, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.211, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.057, n 18). could be the mix.
- skeptic
- leave-one-out range -0.47 to -0.25, sign flips 0; without severely affected donors -0.31 (p 0.214, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.76 (p 2.9e-4, n 18) vs -0.31 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for STK36 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up STK36 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.18 p 0.534 (needs p < 3.2e-4)
Receipts
loading the receipts